SCLX

Scilex Holding Company · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website cilexholding.com
Employees(FY) 109
ISIN US80880W1062

Performance

+8.41%

1W

-22.41%

1M

-51.87%

3M

-15.89%

6M

-55.88%

YTD

-87.05%

1Y

Profile

Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Advanced Technical Analysis

Technical Analysis of SCLX 2024-05-10

Overview:

In analyzing the technical indicators for SCLX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...

See more ...

Recent News & Updates

2024-05-13 21:00
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Produ(Globenewswire)
2024-05-13 20:53
SCLX Stock Earnings: Scilex Holding Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-12 21:00
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock(Globenewswire)
2024-04-25 04:01
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering(Globenewswire)
2024-04-23 20:00
Scilex Holding Company Announces $15 Million Registered Direct Offering(Globenewswire)
2024-04-15 21:00
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Adm(Globenewswire)
2024-04-08 21:00
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool(Globenewswire)
2024-03-26 21:00
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend(Globenewswire)
2024-03-20 21:30
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients(Globenewswire)
2024-03-19 23:00
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed(Globenewswire)
2024-03-19 21:00
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicin(Globenewswire)
2024-03-18 21:00
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation(Globenewswire)
2024-03-17 21:00
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in C(Globenewswire)
2024-03-15 02:45
Scilex Holding Announces Issuance of Halal Certification for its ZTlido product by Circle H International, Inc.(Globenewswire)
2024-03-14 21:00
Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Suc(Globenewswire)
2024-03-05 03:01
Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering(Globenewswire)
2024-03-04 20:00
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba , its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the Firs(Globenewswire)
2024-03-03 20:00
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates(Globenewswire)
2024-03-02 02:25
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento t(Globenewswire)
2024-02-29 04:32
Scilex Holding Company Announces $10 Million Bought Deal Offering(Globenewswire)
2024-02-27 20:00
Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA in Most of Their Stores Throughout the U.S.(Globenewswire)
2024-02-26 20:00
Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)(Globenewswire)
2024-02-26 03:53
Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement(Globenewswire)
2024-02-25 20:00
Scilex Holding Company Announces that ZTlido Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met(Globenewswire)
2024-02-19 20:00
Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido for the Treatment of Chronic Neck Pain(Globenewswire)
2024-01-07 20:00
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024(Globenewswire)
2024-01-01 20:00
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information(Globenewswire)
2023-12-25 22:00
Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB for Acute Treatment of Migraine With or Without (Globenewswire)
2023-12-19 20:00
Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists(Globenewswire)
2023-12-18 20:00
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba as a Liquid Colchicine Formulation Designed for Precision Dosing(Globenewswire)

Page 1 of 4

previousnext